Covered recipient · General Payments record
RACHEL L DUKE
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2021–2024
$2,519.17
- Reported across 65 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $665.04 | 16 |
| Consulting Fee | $490.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $505.23 | 2 |
| TG THERAPEUTICS, INC. | $213.26 | 4 |
| EMD Serono, Inc. | $110.91 | 3 |
| Biogen, Inc. | $100.00 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $82.08 | 2 |
| Amgen Inc. | $60.27 | 2 |
| Celgene Corporation | $31.52 | 1 |
| Genentech, Inc. | $27.60 | 1 |
| ABBVIE INC. | $24.17 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.17 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107046630 | CMS |
| Amgen Inc. | $29.80 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117242670 | CMS |
| Amgen Inc. | $30.47 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117242672 | CMS |
| Biogen, Inc. | $100.00 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104862624 | CMS |
| Celgene Corporation | $31.52 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101095536 | CMS |
| EMD Serono, Inc. | $56.08 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120234296 | CMS |
| EMD Serono, Inc. | $20.66 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120234294 | CMS |
| EMD Serono, Inc. | $34.17 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120247483 | CMS |
| Genentech, Inc. | $27.60 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133182051 | CMS |
| GENZYME CORPORATION | $490.00 | 05/06/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1139912349 | CMS |
| GENZYME CORPORATION | $15.23 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139912335 | CMS |
| Novartis Pharmaceuticals Corporation | $62.78 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086810577 | CMS |
| Novartis Pharmaceuticals Corporation | $19.30 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086810587 | CMS |
| TG Therapeutics, Inc. | $68.75 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136887506 | CMS |
| TG Therapeutics, Inc. | $73.92 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136887406 | CMS |
| TG Therapeutics, Inc. | $30.37 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136887388 | CMS |
| TG Therapeutics, Inc. | $40.22 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136887462 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.